Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

Exclusion Criteria

• •At screening visit, age under legal age of adulthood.
• •HbA1c \<7.0% or greater than (\>) 10% at screening.
• •Less than 1 year on continuous insulin treatment.
• •Use of insulin pump in the last 3 months before screening visit.
• •Participants with incomplete baseline 7-point SMPG profile, defined as participants who do not have 7-point profiles with at least 5 points on at least 2 days in the week before randomization Visit 3.
• •Participants with T1DM: Use of glucose lowering agents other than insulin including use of non-insulin injectable peptides in the last 3 months prior to screening.
• •Participants with T2DM:
• •* Use of glucagon-like peptide-1 (GLP-1) receptor agonists in the last 3 months before screening visit.
• •* Use of oral antidiabetic drugs (OADs) not on stable dose in the last 3 months before screening visit (sulfonylureas was discontinued at baseline).
• •At screening visit, body mass index (BMI) greater than or equal to (\>=) 35 kilogram per meter square (kg/m\^2) in participants with T1DM and \>=40 kg/m\^2 in participants with T2DM.
• •Use of insulin other than:
• •* insulin glargine 100 U/mL and NovoLog/NovoRapid or insulin lispro 100 U/mL as part of a multiple injection regimen in the last 6 months before screening visit, OR
• •* insulin detemir 100 U/mL in the 12 months before screening visit and NovoLog/NovoRapid or insulin lispro 100 U/mL in the last 6 months before screening visit as part of a multiple injection regimen.
• •Status post pancreatectomy.
• •Status post pancreas and/or islet cell transplantation.
• •Hospitalization for recurrent diabetic ketoacidosis in the last 3 months before screening visit.
• •History of severe hypoglycemia requiring Emergency Room admission or hospitalization in the last 3 months before screening visit.
• •Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period.
• •Pregnant or breastfeeding women.
• •Women of childbearing potential not protected by highly effective method(s) of birth control.
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.